Home・Lista de Ações・CytoSorbents Corp

CytoSorbents Corp

Fechado

SetorSaúde

0.36 -7.69

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.35

Máximo

0.37

Indicadores-chave
By Trading Economics
Rendimento	368K -5.1M
Vendas	-370K 8.9M
EPS	-0.08
Margem de lucro	-57.863
Funcionários	129
EBITDA	-204K -3.9M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+87.5% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-16M 23M
Abertura anterior	8.05
Fecho anterior	0.36

CytoSorbents Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de ago. de 2026, 20:51 UTC

Cytosorbents Corp shares declined in after-hours trading, continuing lower since Friday's close, with no specific news identified to explain the movement.

6 de ago. de 2026, 19:16 UTC

Cytosorbents Corp shares are higher during Thursday's session, continuing a strong upward trend since Wednesday's close, with no specific news identified for the increase.

5 de ago. de 2026, 22:06 UTC

Cytosorbents Corp shares are higher in after-market trading, reaching a high of 2.63% following an initial dip. The stock remains above its 20-day moving average.

4 de ago. de 2026, 21:01 UTC

Cytosorbents Corp shares are higher in after-market trading amid positive market sentiment linked to U.S.-Iran negotiations and declining crude oil prices.

3 de ago. de 2026, 19:56 UTC

Cytosorbents Corp shares are higher during Monday's session, tracking a broader market uptick despite being below the 20-day moving average.

31 de jul. de 2026, 20:06 UTC

Cytosorbents Corp. shares are trading roughly flat amid no specific news. The broader market also closed near unchanged since Thursday.

29 de jul. de 2026, 20:08 UTC

Cytosorbents Corp shares are lower today, following an early peak and trading below the 20-day moving average. No specific news was identified for the decline.

28 de jul. de 2026, 18:46 UTC

Cytosorbents Corp is trading higher during Tuesday's session, recovering from an earlier dip. No specific news was identified to explain the movement.

27 de jul. de 2026, 18:41 UTC

Cytosorbents Corp shares are lower today amid notable volatility, with no specific news identified to explain the decline during Monday's session.

24 de jul. de 2026, 19:06 UTC

Cytosorbents Corp shares are lower, marking three consecutive daily declines amid a broader market pullback influenced by falling crude oil prices.

22 de jul. de 2026, 20:13 UTC

Cytosorbents Corp shares are lower in after-market hours amid rising crude oil prices and escalating U.S.-Iran tensions. The stock remains below its 20-day moving average.

21 de jul. de 2026, 18:31 UTC

Cytosorbents Corp shares are higher today, reflecting broader market optimism despite earlier fluctuations. Strong buying in technology stocks supports this upward movement.

20 de jul. de 2026, 19:16 UTC

News

Cytosorbents plans to report second-quarter 2026 results on August 6. The company is also pursuing FDA and Health Canada approval for its DrugSorb®-ATR device.

Comparação entre Pares

Variação de preço

CytoSorbents Corp Previsão

Preço-alvo

By TipRanks

87.5% parte superior

Previsão para 12 meses

Média 0.75 USD 87.5%

Máximo 0.75 USD

Mínimo 0.75 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para CytoSorbents Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para CytoSorbents Corp - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.